1 / 5

Pharmacotherapy for posttraumatic stress disorder: review with clinical applications

Pharmacotherapy for posttraumatic stress disorder: review with clinical applications. Matthew Jeffreys, MD; Bruce Capehart, MD, MBA; Matthew J. Friedman, MD, PhD. Aim

ronan-pruitt
Download Presentation

Pharmacotherapy for posttraumatic stress disorder: review with clinical applications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmacotherapy for posttraumatic stress disorder: review with clinical applications Matthew Jeffreys, MD; Bruce Capehart, MD, MBA; Matthew J. Friedman, MD, PhD

  2. Aim • Review pharmacotherapy recommendations from 2010 Department of Veterans Affairs (VA)/Department of Defense (DOD) Clinical Practice Guideline for posttraumatic stress disorder (PTSD). • Provide practical PTSD treatment recommendations for clinicians. • Relevance • While evidence-based, trauma-focused psychotherapy is preferred, pharmacotherapy is also important PTSD treatment option.

  3. Stepped care for pharmacotherapy in PTSD. Adapted from VA/DOD Clinical Practice Guideline for PTSD.

  4. Recommendations • First-line: • Selective serotonin reuptake inhibitors. • Venlafaxine. • Selective serotonin-norepinephrine reuptake inhibitor. • Second-line: • Nefazodone, mirtazapine, tricyclic antidepressants, monoamine oxidase inhibitors. • Less evidence for usefulness and potentially greater side effect burden. • Prazosin beneficial for nightmares. • Benzodiazepines, antipsychotics not recommended.

  5. Conclusions • Effective screening for PTSD and trauma-related distress helps patient and staff understand emotional factors affecting recovery. • First- and second-line pharmacotherapy must be distinguished and discussed with patients in context of strong treatment alliance. • Co-occurring disorders (e.g., major depressive disorder, substance use disorder, and traumatic brain injury) must be treated to maximize PTSD treatment outcomes.

More Related